Equibles does not estimate personal net worth.
Get an email with a short summary when Fulgent Genetics, Inc. publishes a filing, an earnings call transcript or a press release.
Get FLGT alertsPaul Kim is recorded as CFO at Fulgent Genetics, Inc. (FLGT). The newest filing on record that lists Paul Kim as CFO at Fulgent Genetics, Inc. (FLGT) is dated March 31, 2026. The proxy statement of Fulgent Genetics, Inc. reports total compensation of $2,773,352 for Paul Kim in fiscal 2025, including a base salary of $600,000. Disclosed compensation is on record for 8 fiscal years. Paul Kim has spoken on 27 earnings calls across 1 company, most recently for Fulgent Genetics, Inc. on November 5, 2026. Fulgent Genetics, Inc. is classified in the Diagnostics & Research industry within the Healthcare sector. Other leadership on record at Fulgent Genetics, Inc. includes Ming Hsieh (CEO), Jian Xie (COO), Hanlin Gao (Board Member) and 5 others.
“Revenue in the third quarter of 2026 totaled $90.4 million, including $21.8 million from BACO Diagnostics and Strata DX, compared to $85.4 million in the second quarter of 2026, which included $16.4 million from BACO Diagnostics and Strata DX.”
“Revenue in the second quarter of 2026 totaled $85.4 million, including $16.9 million from BACO Diagnostics and Strata DX, compared to $71.1 million in the first quarter of 2026.”
“Revenue in the first quarter of 2026 totaled $71.1 million, including $2.6 million from BACO Diagnostics and Strata DX, compared to $83.3 million in the fourth quarter of 2025.”
“Full year revenue for 2025 totaled $322.7 million, growing approximately 14% compared to revenue of $283.5 million in 2024, which fell slightly short of the updated guidance we provided on last quarter's earnings call, but ahead of the original guidance we provided at the beginning of 2025.”
“Revenue in the third quarter of 2025 totaled $84.1 million compared to $81.8 million in the second quarter of 2025.”
Start not stated–present
Last confirmed March 31, 2026
Diagnostics & Research · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Fulgent Genetics, Inc. (FLGT) | Chief Financial Officer | $600,000 | $2,773,352 |
| 2024 | Fulgent Genetics, Inc. (FLGT) | Chief Financial Officer | $600,000 | $2,353,644 |
| 2023 | Fulgent Genetics, Inc. (FLGT) | Chief Financial Officer | $600,000 | $1,779,613 |
| 2022 | Fulgent Genetics, Inc. (FLGT) | Chief Financial Officer | $579,167 | $3,872,587 |
| 2021 | Fulgent Genetics, Inc. (FLGT) | Chief Financial Officer | $424,878 | $669,982 |
| 2020 | Fulgent Genetics, Inc. (FLGT) | Chief Financial Officer | $210,000 | $1,390,456 |
| 2019 | Fulgent Genetics, Inc. (FLGT) | Chief Financial Officer | $210,000 | $823,481 |
| 2018 | Fulgent Genetics, Inc. (FLGT) | Chief Financial Officer | $210,000 | $241,124 |
